(Reuters) - Results from a pivotal Phase III study presented at the European Hematology Association congress in Vienna showed 50 to 75 milligrams once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in people with chronic ITP.
The placebo-controlled trial involved 114 adults and patients studied had previously received and failed current standard ITP treatments.
Read more at Reuters.com Business News
The placebo-controlled trial involved 114 adults and patients studied had previously received and failed current standard ITP treatments.
Read more at Reuters.com Business News
No comments:
Post a Comment